DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
AMG-157
2
Antibody
Investigational
Unknown
Unknown
Asthma
Thymic stromal lymphopoietin inhibitor
AMG-157
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PARSATUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Epidermal growth factor-like protein 7 inhibitor
PARSATUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
435M4HCP2M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
L-DOS47
2
Unknown
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms; Adenocarcinoma of Lung
Unknown
L-DOS47
×
Maximum Phase:
2
First Approval:
None
UNII:
95E1ZQM329
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SB-773812
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Dopamine D2 receptor antagonist
SB-773812
×
Maximum Phase:
2
First Approval:
None
UNII:
ZNP5SNF9FY
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LIFASTUZUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms
Sodium-dependent phosphate transport protein 2B binding agent
LIFASTUZUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
7IUT83FK6S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMX-001
2
Small molecule
Investigational
Unknown
Unknown
Glioblastoma; Head and Neck Neoplasms
Metalloporphyrin antioxidant (antitumor, radioprotectant)
BMX-001
×
Maximum Phase:
2
First Approval:
None
UNII:
MIJ02RO47F
Molecule Type:
Small molecule
Molecular Formula:
C64H76Cl5MnN8O4
Molecular Weight:
1253.57
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
MS-1819
2
Unknown
Investigational
Unknown
Unknown
Pancreatitis, Chronic
Unknown
MS-1819
×
Maximum Phase:
2
First Approval:
None
UNII:
V6AP1D8NNW
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GOSSYPOL ACETIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Central Nervous System Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Adrenal Cortex Neoplasms; Gliosarcoma; Small Cell Lung Carcinoma
Unknown
GOSSYPOL ACETIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
S7RL72610R
Molecule Type:
Small molecule
Molecular Formula:
C42H42O14
Molecular Weight:
770.78
AlogP:
7.7
PSA:
191.94
HBD:
0.0
HBA:
#RotB:
11.0
Source:
BALIPODECT
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Phosphodiesterase 10A inhibitor
BALIPODECT
×
Maximum Phase:
2
First Approval:
None
UNII:
6650W303H0
Molecule Type:
Small molecule
Molecular Formula:
C23H17FN6O2
Molecular Weight:
428.43
AlogP:
3.42
PSA:
79.76
HBD:
0.0
HBA:
#RotB:
5.0
Source:
EXBIVIRUMAB
2
Antibody
Investigational
Unknown
Unknown
Hepatitis B, Chronic
Unknown
EXBIVIRUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
5Q374M1S1P
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUTEOLIN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LUTEOLIN
×
Maximum Phase:
2
First Approval:
None
UNII:
KUX1ZNC9J2
Molecule Type:
Small molecule
Molecular Formula:
C15H10O6
Molecular Weight:
286.24
AlogP:
2.28
PSA:
111.13
HBD:
4.0
HBA:
#RotB:
1.0
Source:
BEVIRIMAT
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
BEVIRIMAT
×
Maximum Phase:
2
First Approval:
None
UNII:
S125DW66N8
Molecule Type:
Small molecule
Molecular Formula:
C36H56O6
Molecular Weight:
584.84
AlogP:
8.14
PSA:
100.9
HBD:
2.0
HBA:
#RotB:
6.0
Source:
HYDRONIDONE
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Hepatitis B, Chronic
Unknown
HYDRONIDONE
×
Maximum Phase:
2
First Approval:
None
UNII:
RXQ128313W
Molecule Type:
Small molecule
Molecular Formula:
C12H11NO2
Molecular Weight:
201.22
AlogP:
1.85
PSA:
42.23
HBD:
1.0
HBA:
#RotB:
1.0
Source:
SB-649868
2
Small molecule
Investigational
Unknown
Unknown
Sleep Wake Disorders; Sleep Initiation and Maintenance Disorders
Orexin receptor 1 antagonist
SB-649868
×
Maximum Phase:
2
First Approval:
None
UNII:
1L1V1K2M4V
Molecule Type:
Small molecule
Molecular Formula:
C26H24FN3O3S
Molecular Weight:
477.56
AlogP:
5.43
PSA:
75.44
HBD:
1.0
HBA:
#RotB:
5.0
Source:
FOSBRETABULIN
2
Small molecule
Investigational
Unknown
Unknown
Ovarian Neoplasms; Neoplasms; Neuroendocrine Tumors; Thyroid Neoplasms
Unknown
FOSBRETABULIN
×
Maximum Phase:
2
First Approval:
None
UNII:
I5590ES2QZ
Molecule Type:
Small molecule
Molecular Formula:
C18H21O8P
Molecular Weight:
396.33
AlogP:
3.36
PSA:
103.68
HBD:
2.0
HBA:
#RotB:
8.0
Source:
FLAXSEED
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
FLAXSEED
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TGN-1412
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Neoplasms; Psoriasis; Lupus Erythematosus, Systemic
T-cell-specific surface glycoprotein CD28 agonist
TGN-1412
×
Maximum Phase:
2
First Approval:
None
UNII:
POO0DOD3AS
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OLPASIRAN
2
Oligonucleotide
Investigational
Unknown
Unknown
Cardiovascular Diseases
LPA mRNA rnai inhibitor
OLPASIRAN
×
Maximum Phase:
2
First Approval:
None
UNII:
8M4GC1EOB4
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
V0018
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
V0018
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEPINEMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Melanoma; Multiple Sclerosis; Neoplasms; Osteosarcoma; Huntington Disease
Semaphorin-4D inhibitor
PEPINEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
BPZ4A29SYE
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELSUBRUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Erythematosus, Systemic
Tyrosine-protein kinase BTK inhibitor
ELSUBRUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
1487U1Q3IQ
Molecule Type:
Small molecule
Molecular Formula:
C17H19N3O2
Molecular Weight:
297.36
AlogP:
2.16
PSA:
79.19
HBD:
2.0
HBA:
#RotB:
3.0
Source:
DAGLUTRIL
2
Small molecule
Investigational
Unknown
Unknown
Hypertension
Endothelin-converting enzyme 1 inhibitor
DAGLUTRIL
×
Maximum Phase:
2
First Approval:
None
UNII:
KKV299446X
Molecule Type:
Small molecule
Molecular Formula:
C31H38N2O6
Molecular Weight:
534.65
AlogP:
4.3
PSA:
113.01
HBD:
2.0
HBA:
#RotB:
11.0
Source:
METHYLINOSITOL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
METHYLINOSITOL
×
Maximum Phase:
2
First Approval:
None
UNII:
TF9HZN9T0M
Molecule Type:
Small molecule
Molecular Formula:
C7H14O6
Molecular Weight:
194.18
AlogP:
-3.18
PSA:
110.38
HBD:
5.0
HBA:
#RotB:
1.0
Source:
INDISULAM
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Stomach Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Leukemia; Melanoma
Unknown
INDISULAM
×
Maximum Phase:
2
First Approval:
None
UNII:
WJ98J3NM90
Molecule Type:
Small molecule
Molecular Formula:
C14H12ClN3O4S2
Molecular Weight:
385.85
AlogP:
2.27
PSA:
122.12
HBD:
3.0
HBA:
#RotB:
4.0
Source:
EZATIOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Myelodysplastic Syndromes
Unknown
EZATIOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
057D10I8S8
Molecule Type:
Small molecule
Molecular Formula:
C27H35N3O6S
Molecular Weight:
529.66
AlogP:
2.5
PSA:
136.82
HBD:
3.0
HBA:
#RotB:
15.0
Source:
CK-2127107
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CK-2127107
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELINZANETANT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ELINZANETANT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C33H35F7N4O3
Molecular Weight:
668.65
AlogP:
6.06
PSA:
69.14
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ALPHA CYCLODEXTRIN
2
Oligosaccharide
Investigational
Unknown
Unknown
Unknown
Unknown
ALPHA CYCLODEXTRIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Oligosaccharide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AT7519M
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
AT7519M
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ENTOLIMOD
2
Unknown
Investigational
Unknown
Unknown
Substance-Related Disorders; Neoplasms; Colorectal Neoplasms
Toll-like receptor 5 agonist
ENTOLIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
R1UQ6D1ECM
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EMIVIRINE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
EMIVIRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
X87G8IX72O
Molecule Type:
Small molecule
Molecular Formula:
C17H22N2O3
Molecular Weight:
302.37
AlogP:
2.24
PSA:
64.09
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ONFEKAFUSP ALFA
2
Protein
Investigational
Unknown
Unknown
Glioblastoma; Glioma; Sarcoma
Unknown
ONFEKAFUSP ALFA
×
Maximum Phase:
2
First Approval:
None
UNII:
6HXC0O6JMV
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVADOMIDE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Renal Insufficiency; Melanoma
Unknown
AVADOMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
28DZS29F59
Molecule Type:
Small molecule
Molecular Formula:
C14H14N4O3
Molecular Weight:
286.29
AlogP:
0.26
PSA:
107.08
HBD:
2.0
HBA:
#RotB:
1.0
Source:
LABETUZUMAB GOVITECAN
2
Antibody
Investigational
Unknown
Unknown
Colonic Neoplasms; Rectal Neoplasms
Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
LABETUZUMAB GOVITECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
8E3HI6QQ9J
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DAVALINTIDE ACETATE
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
DAVALINTIDE ACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
4QM48103XT
Molecule Type:
Protein
Molecular Formula:
C154H252N50O51S2
Molecular Weight:
3684.14
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
1
2
…
138
139
140
141
142
143
144
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA